REGENXBIO, Inc. RGNX 深 沪
等待开盘 05-15 09:30:00 美东时间
6.245
-3.795
-37.80%
华盛通- 最 高8.13
- 今 开8.08
- 成交量 1032.12万股
- 最 低 6.015
- 昨 收 10.04
- 总市值 3.22亿
- 52周最高 16.19
- 市盈率 静 --
- 换手率 20.00%
- 52周最低 6.015
- 委 比 21.54%
- 总股本 5161.72万
- 历史最高 85.10
- 量 比 7.10
- 振 幅 21.07%
- 历史最低 5.035
- 每 手 1
- 风险率 2.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多REGENXBIO Advances Duchenne Gene Therapy Toward Accelerated Approval
REGENXBIO reports positive Phase 3 Duchenne trial data as RGX-202 met its primary endpoint with strong safety results.
今天 00:03
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Alpha Compute (NASDAQ:ALP) shares increased by 71.3% to $0.46 during T...
05-14 20:05
Regenxbio's Shares Topline And Interim Functional Data From Pivotal Phase 3 Portion Of Phase 1/2/3 Affinity Duchenne Trial Of RGX-202 For Duchenne Muscular Dystrophy, Meeting The Primary Endpoint With High Statistical Significance
REGENXBIO Inc. (NASDAQ:RGNX) announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY DUCHENNE® trial of RGX-202, a potential best-in-class gene
05-14 19:12
Earnings Scheduled For May 14, 2026
Companies Reporting Before The Bell • Urban One (NASDAQ:UONEK) is expected to r...
05-14 19:11
Regenxbio Reports Duchenne Gene Therapy Progress As Stock Slides On Mixed Signals
Regenxbio releases new Duchenne trial data showing improved motor function and stable heart measures in early-stage patients.
03-12 02:19
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Relmada Therapeutics, Xenon Pharmaceuticals, Dianthus Therapeutics And Other Big Stocks Moving Higher On Monday
US stocks tumble as Dow falls 650 points. Relmada Therapeutics stock rises 40.8% on promising cancer treatment data. Hims & Hers and Xenon Pharma jump over 40%.
03-09 22:05
股价盘前飙升34%！uniQure BV等公司因 FDA官员离职股价大涨！
（来源：invest wallstreet） uniQure BV (NASDAQ:QURE)股价周一飙升36%,此前有报道称美国食品药品监督管理局疫苗和基因治...
03-09 20:41
美股大行评级 | 潜在涨幅183%！迈威尔科技获10家机构上调目标价最高至164美元；伯灵顿百货、好市多、Ciena、Samsara等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持BridgeBio Oncology"买入"评级，目标价从27美元升至29美元；韦德布什：维持WAVE Life Sciences"跑赢大市"评级，目标价从33美元升至35美元
03-09 11:47
